CWA
PMCB icon

Carolina Wealth Advisors’s PharmaCyte Biotech PMCB Stock Holding History

Carolina Wealth Advisors’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2
Closed -$4 – 267
2023
Q3 		$4 Hold
2
– – ﹤0.01% 266
2023
Q2 		$6 Buy
+2
New +$6 ﹤0.01% 255
2022
Q4 		– Sell
-2
Closed – – 256
2022
Q3 		$0 Hold
2
– – ﹤0.01% 269
2022
Q2 		$0 Hold
2
– – ﹤0.01% 285
2022
Q1 		$0 Buy
+2
New +$4 ﹤0.01% 297

Other funds holding PMCB

KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Carolina Wealth Advisors's PMCB Position: Q4 2023 in Review

Carolina Wealth Advisors sold out of PharmaCyte Biotech (PMCB) in Q4 2023, closing a stake of 2 shares — an estimated $4 sold.

Carolina Wealth Advisors first reported a position in PMCB in Q1 2022 and held it in 5 quarters. The position peaked at $6 in Q2 2023. 32 funds tracked by Wall St. Rank hold PMCB as of Q4 2023.

  • Carolina Wealth Advisors reported no remaining PharmaCyte Biotech position as of Q4 2023 after selling out during the quarter.
  • Carolina Wealth Advisors sold 2 PharmaCyte Biotech shares in Q4 2023, an estimated $4.
  • Carolina Wealth Advisors first reported a position in PharmaCyte Biotech in Q1 2022 and held it in 5 quarters.
  • Carolina Wealth Advisors's PharmaCyte Biotech position peaked at $6 in Q2 2023.
  • 32 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q4 2023.

Based on Carolina Wealth Advisors's 13F filing for Q4 2023, filed 23 Jan 2024.